More than 60 percent of patients with Epstein-Barr virus–associated lymphoproliferative disorder (EBV-LPD) that was not responding to standard rituximab (Rituxan) treatment responded to a new type of immunotherapy called ...
16 hours ago
A cell surface protein known to regulate innate immune responses also affects the adaptive immune system
Understanding the immune response triggered by the mosquito-borne Chikungunya virus (CHIKV) is key to developing effective treatments. Now, an international team led by A*STAR researchers has shown that a ...
Apr 15, 2015